SEC Form 4
uniQure N.V. (QURE) insider trading
In the 12 months to Nov 21, 2026, 6 QURE insiders reported open-market sales of $17.9M across 14 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $17.9M
- 14 filings · 6 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 14 of 14
- All $17.9M sold was pre-arranged
Who traded QURE, and when
- Sale
- Sale, pre-arranged (10b5-1)
QURE daily close from Nov 21, 2025 to Nov 20, 2026, between $9.03 and $51.05, last $19.35. 14 sale and 0 purchase filings by 6 insiders, marked at their filing dates. Matthew C. Kapusta, CEO, Managing Director: sold $12.1M across 3 filings, first filed Jun 22, 2026, last Jul 7, 2026. Walid Abi-Saab, Chief Medical Officer: sold $2.5M across 2 filings, first filed May 12, 2026, last Jul 2, 2026. Jack Kaye, Director: sold $1.5M across 4 filings, first filed Jan 12, 2026, last Jul 2, 2026. Robert Gut, Director: sold $827.2K across 2 filings, first filed Jan 14, 2026, last Jun 12, 2026. Madhavan Balachandran, Director: sold $805.0K across 2 filings, first filed Jun 17, 2026, last Jun 22, 2026. David D. Meek, Director: sold $193.0K across 1 filing, first filed Nov 10, 2026, last Nov 10, 2026.
Largest mark · tap a row for others
Matthew C. Kapusta · CEO, Managing Director
Filing 1 of 2 within a week · $11,142,786 total
Sale $9,371,612
206,100 shares
Filed Jun 22, 2026 · traded Jun 17
Pre-arranged (10b5-1) · close on filing date $44.39
Matthew C. Kapusta · CEO, Managing Director
CEO, Managing Director
$12.1M soldWalid Abi-Saab · Chief Medical Officer
Chief Medical Officer
$2.5M soldJack Kaye · Director
Director
$1.5M soldRobert Gut · Director
Director
$827.2K soldMadhavan Balachandran · Director
Director
$805.0K soldDavid D. Meek · Director
Director
$193.0K soldOpen-market trades
14 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Matthew C. Kapusta | CEO, Managing Director | $12.1M | — | 3 | 100% of sales | |
| Walid Abi-Saab | Chief Medical Officer | $2.5M | — | 2 | 100% of sales | |
| Jack Kaye | Director | $1.5M | — | 4 | 100% of sales | |
| Robert Gut | Director | $827.2K | — | 2 | 100% of sales | |
| Madhavan Balachandran | Director | $805.0K | — | 2 | 100% of sales | |
| David D. Meek | Director | $193.0K | — | 1 | 100% of sales |
| Filed | Insider | Type | Shares | Value | Held after | Source |
|---|---|---|---|---|---|---|
traded | David D. Meek Director | SalePre-arranged (10b5-1) | 9,080 ordinary shares | $193.0K | 30,667 | |
traded | Matthew C. Kapusta CEO, Managing Director | SalePre-arranged (10b5-1) | 21,082 ordinary shares | $952.1K | 526,827 | |
traded | Jack Kaye Director | SalePre-arranged (10b5-1) | 21,167 ordinary shares | $983.0K | 25,996 | |
traded | Walid Abi-Saab Chief Medical Officer | SalePre-arranged (10b5-1) | 30,000 ordinary shares | $1.4M | 168,235 | |
traded | Matthew C. Kapusta CEO, Managing Director | SalePre-arranged (10b5-1) | 35,412 ordinary shares | $1.8M | 519,227 | |
traded | Jack Kaye Director | SalePre-arranged (10b5-1) | 5,295 ordinary shares | $225.4K | 25,996 | |
traded | Madhavan Balachandran Director | SalePre-arranged (10b5-1) | 11,685 ordinary shares | $526.5K | 43,254 | |
traded | Matthew C. Kapusta CEO, Managing Director | SalePre-arranged (10b5-1) | 206,100 ordinary shares | $9.4M | 558,810 | |
traded | Madhavan Balachandran Director | SalePre-arranged (10b5-1) | 10,000 ordinary shares | $278.5K | 43,254 | |
traded | Robert Gut Director | SalePre-arranged (10b5-1) | 7,552 ordinary shares | $196.7K | 32,342 | |
traded | Jack Kaye Director | SalePre-arranged (10b5-1) | 2,645 ordinary shares | $79.4K | 20,439 | |
traded | Walid Abi-Saab Chief Medical Officer | SalePre-arranged (10b5-1) | 45,000 ordinary shares | $1.1M | 169,669 | |
traded | Robert Gut Director | SalePre-arranged (10b5-1) | 25,613 ordinary shares | $630.5K | 32,342 | |
traded | Jack Kaye Director | SalePre-arranged (10b5-1) | 6,390 ordinary shares | $174.3K | 20,439 |
Shares are as filed (ordinary shares or ADS); values are as converted to US$ in the filing.
GET /stocks/filings/vX/form-4?tickers=QURE&filing_date.gte=2025-11-21&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"QURE"
],
"issuer_cik": "0001590560",
"owner_cik": "0001555337",
"accession_number": "0000904454-26-000605",
"form_type": "4",
"filing_date": "2026-11-10",
"period_of_report": "2026-11-06",
"issuer_name": "uniQure N.V.",
"issuer_trading_symbol": "QURE",
"owner_name": "Meek David D.",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Ordinary Shares",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-11-06",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 9080,
"transaction_price_per_share": 21.25,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 30667,
"transaction_value": 192950,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The shares were sold pursuant to a sales plan adopted by the Reporting Person on May 26, 2026 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934."
}
]
},
{
"tickers": [
"QURE"
],
"issuer_cik": "0001590560",
"owner_cik": "0001536290",
"accession_number": "0000904454-26-000397",
"form_type": "4",
"filing_date": "2026-07-07",
"period_of_report": "2026-07-02",
"issuer_name": "uniQure N.V.",
"issuer_trading_symbol": "QURE",
"owner_name": "Kapusta Matthew C",
"is_director": true,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "CEO, Managing Director",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Ordinary Shares",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-07-02",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 9200,
"transaction_price_per_share": 44.43,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 531109,
"transaction_value": 408756,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on October 5, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934."
},
{
"id": "F2",
"description": "The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $44.10 to $44.80. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 50 records
- Option exercises17 records
- Tax withholding (sold to cover)20 records
- Grants and awards13 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has uniQure N.V.'s CEO sold stock?
Yes. Matthew C. Kapusta (CEO) sold 262,594 shares ($12.1M) between Jun 2026 and Jul 2026, all under a pre-arranged 10b5-1 plan.
How current is QURE’s insider data?
These are QURE Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track QURE insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for QURE every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.